Samantha Sarcognato

Samantha Sarcognato

Auto-generated profile, based on publicly available information

Samantha Sarcognato

Department of Pathology, Azienda ULSS2 Marca Trevigiana, 31100 Treviso, Italy

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Pathologica
Verified
Journal Article
Open access
PDF file
SSSamantha Sarcognato
Samantha Sarcognato
DSDiana Sacchi
Diana Sacchi
Matteo FassanMatteo Fassan
Matteo Fassan
LFLuca Fabris
Luca Fabris
MCMassimiliano Cadamuro
Massimiliano Cadamuro
MGMaria Guido
Maria Guido
Liver cancer represents the third leading cause of cancer-related death worldwide. Cholangiocarcinoma (CCA) is the second most common type of liver cancer after hepatocellular carcinoma, accounting for 10-15% of all primary liver malignancies. Both the incidence and mortality of CCA have been steadily increasing during the last decade. Moreover, most CCAs are diagnosed at an advanced stage, when therapeutic options are very limited. CCA may arise from any tract of the biliary system and it is classified into intrahepatic, perihilar, and distal CCA, according to the anatomical site of origin. This topographical classification also reflects distinct genetic and histological features, risk factors, and clinical outcomes. This review focuses on histopathology of CCA, its differential diagnoses, and its diagnostic pitfalls.

1 June 2021 in Pathologica
Verified
Journal Article
Open access
PDF file
SSSamantha Sarcognato
Samantha Sarcognato
DSDiana Sacchi
Diana Sacchi
FGFederica Grillo
Federica Grillo
NCNora Cazzagon
Nora Cazzagon
LFLuca Fabris
Luca Fabris
MGMaria Guido
Maria Guido
Autoimmune cholestatic liver diseases are rare hepato-biliary disorders characterized by a progressive, inflammatory destruction of bile ducts. Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are the main autoimmune cholestatic liver diseases. Both may evolve into secondary biliary cirrhosis and its complications. Therapeutic options are limited and liver transplantation remains the only definitive treatment for PBC and PSC. Most PBC and PSC patients have a typical presentation, which does not require liver biopsy. However, in routine clinical practice, important variants or specific subgroups that benefit from liver biopsy for proper management may be observed. Herein, we provide a general overview of clinical and pathological characteristic of PBC and PSC, highlighting the most important features for routine diagnostic practice.

1 June 2021 in Pathologica
Verified
Journal Article
Open access
PDF file
CCClaudia Covelli
Claudia Covelli
DSDiana Sacchi
Diana Sacchi
SSSamantha Sarcognato
Samantha Sarcognato
NCNora Cazzagon
Nora Cazzagon
FGFederica Grillo
Federica Grillo
MGMaria Guido
Maria Guido
Autoimmune hepatitis (AIH) is a relatively rare non-resolving chronic liver disease, which mainly affects women. It is characterized by hypergammaglobulinemia, circulating autoantibodies, interface hepatitis on liver histology and a favourable response to immunosuppression. The putative mechanism for the development of autoimmune hepatitis is thought to be the interaction between genetic predisposition, environmental triggers and failure of the native immune system. AIH still remains a major diagnostic and therapeutic challenge, mainly because it is a very heterogeneous disease. Prompt and timely diagnosis is crucial since, if left untreated, AIH has a high mortality rate. Histological demonstration of hepatitis is required for the diagnosis of AIH and, therefore, liver biopsy is mandatory in the initial diagnostic work-up, before treatment. In this review, we summarize the histological features of AIH with the main aim of highlighting the most important clinical-pathological hallmarks useful in the routine diagnostic practice.

1 June 2021 in Pathologica
Verified
Journal Article
Open access
PDF file
SRSalvatore Lorenzo Renne
Salvatore Lorenzo Renne
SSSamantha Sarcognato
Samantha Sarcognato
DSDiana Sacchi
Diana Sacchi
MGMaria Guido
Maria Guido
MRMassimo Roncalli
Massimo Roncalli
Luca Di TommasoLuca Di Tommaso
Luca Di Tommaso
HCC incidence rates have been rising in the past 3 decades and by 2025 > 1 million individuals will be affected annually. High-throughput sequencing technologies led to the identification of several molecular HCC subclasses that can be broadly grouped into 2 major subgroups, each characterized by specific morphological and phenotypical features. It is likely that this increasing knowledge and a more appropriate characterization of HCC at the pathological level will impact HCC patient management.

1 June 2021 in Pathologica
Verified
Journal Article
Open access
PDF file
ICIvana Cataldo
Ivana Cataldo
SSSamantha Sarcognato
Samantha Sarcognato
DSDiana Sacchi
Diana Sacchi
MCMatilde Cacciatore
Matilde Cacciatore
FBFrancesca Baciorri
Francesca Baciorri
MGMaria Guido
Maria Guido
Non-alcoholic fatty liver disease (NAFLD) encompasses a spectrum of different conditions which are characterized by hepatic steatosis in the absence of secondary causes. It is currently the most common chronic liver disease worldwide, and its estimated prevalence is about 1.5-6.5%. The only histological finding of steatosis (“simple” steatosis) represents the uncomplicated form of NAFLD, while non-alcoholic steatohepatitis (NASH) is its inflammatory subtype associated with disease progression to cirrhosis and hepatocellular carcinoma (HCC), and represents the major indication for liver transplantation. NASH is still a diagnostic and therapeutic challenge for clinicians and liver biopsy is currently the only accepted method to reliably distinguish NASH from “simple” steatosis. From the histological perspectives, NAFLD and NASH continue to be an area of active interest for pathologists, with a specific focus on better methods of evaluation, morphologic clues to pathogenesis, and predictors of fibrosis progression. This review focuses on histopathology of NAFLD in adults, with the aim to provide a practical diagnostic approach useful in the clinical routine

12 November 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
Daniela GabbiaDaniela Gabbia
Daniela Gabbia
SCSara Carpi
Sara Carpi
SSSamantha Sarcognato
Samantha Sarcognato
IZIlaria Zanotto
Ilaria Zanotto
KSKatia Sayaf
Katia Sayaf
Sara De MartinSara De Martin
Sara De Martin
Liver fibrosis is the result of a chronic pathological condition caused by the activation of hepatic stellate cells (HSCs), which induces the excessive deposition of extracellular matrix. Fibrogenesis is sustained by an exaggerated production of reactive oxidative species (ROS) by NADPH oxidases (NOXs), which are overactivated in hepatic inflammation. In this study, we investigated the antifibrotic properties of two phenolic compounds of natural origin, tyrosol (Tyr) and hydroxytyrosol (HTyr), known for their antioxidant and anti-inflammatory effects. We assessed Tyr and HTyr antifibrotic and antioxidant activity both in vitro, by a co-culture of LX2, HepG2 and THP1-derived Mϕ macrophages, set up to simulate the hepatic microenvironment, and in vivo, in a mouse model of liver fibrosis obtained by carbon tetrachloride treatment. We evaluated the mRNA and protein expression of profibrotic and oxidative markers (α-SMA, COL1A1, NOX1/4) by qPCR and/or immunocytochemistry or immunohistochemistry. The expression of selected miRNAs in mouse livers were measured by qPCR. Tyr and HTyr reduces fibrogenesis in vitro and in vivo, by downregulating all fibrotic markers. Notably, they also modulated oxidative stress by restoring the physiological levels of NOX1 and NOX4. In vivo, this effect was accompanied by a transcriptional regulation of inflammatory genes and of 2 miRNAs involved in the control of oxidative stress damage (miR-181-5p and miR-29b-3p). In conclusion, Tyr and HTyr exert antifibrotic and anti-inflammatory effects in preclinical in vitro and in vivo models of liver fibrosis, by modulating hepatic oxidative stress, representing promising candidates for further development.